Thursday, November 21, 2013 8:40:16 AM
Fact:
Nasrat became CEO as well as transfering over a dozen drugs that is free of cost, (ofcourcse this cost is paid 3 years from now).
Fact:
EPIC extended the alliance deal.
Fact:
EPIC is taking on all costs with the transfer of Nasrats's drugs.
Fact:
Human trials start December 5th
Fact:
Epic is selling *some* shares to pay the milestone payments.
Fact:
Form 4s were placed near the same time of the CC this week by Epic. One milestone payment has alrdy been paid and one is on the way.
Opinion:
The above are all facts that I call real DD and not me speculating if MM's, or flipper's, or shorters, or "the poison pill" has anything to do with the PPS.
Also opinion:
The poison pill has nothing to do with the 6 million shares traded yesterday. Nasrat explained what it is used for as well I just posted you the “facts” of what a poison pill is used for.
Correct ! Opinions are allowed and carry weight, but opinions followed by facts usually carry more.
Nasrat became CEO as well as transfering over a dozen drugs that is free of cost, (ofcourcse this cost is paid 3 years from now).
Fact:
EPIC extended the alliance deal.
Fact:
EPIC is taking on all costs with the transfer of Nasrats's drugs.
Fact:
Human trials start December 5th
Fact:
Epic is selling *some* shares to pay the milestone payments.
Fact:
Form 4s were placed near the same time of the CC this week by Epic. One milestone payment has alrdy been paid and one is on the way.
Opinion:
The above are all facts that I call real DD and not me speculating if MM's, or flipper's, or shorters, or "the poison pill" has anything to do with the PPS.
Also opinion:
The poison pill has nothing to do with the 6 million shares traded yesterday. Nasrat explained what it is used for as well I just posted you the “facts” of what a poison pill is used for.
Correct ! Opinions are allowed and carry weight, but opinions followed by facts usually carry more.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 11:00:24 AM
- Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product • Newsfile • 06/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
